Astrazeneca (AZN) Other Non-Current Liabilities (2015 - 2025)

Astrazeneca's Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $85.0 million for Q4 2025.

• In Q4 2025, Other Non-Current Liabilities fell 90.77% year-over-year to $85.0 million; the TTM figure through Dec 2025 stood at $85.0 million (down 90.77% YoY), while the FY2025 annual figure was $85.0 million, down 90.77% from the prior year.
• Other Non-Current Liabilities was $85.0 million for Q4 2025 at Astrazeneca, down from $921.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.3 billion in Q4 2022 to a low of $85.0 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $1.7 billion across 5 years, with a median of $1.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 111.81% in 2022, then sank 90.77% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $2.0 billion in 2021, then surged by 111.81% to $4.3 billion in 2022, then plunged by 72.58% to $1.2 billion in 2023, then fell by 21.35% to $921.0 million in 2024, then tumbled by 90.77% to $85.0 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $85.0 million (Q4 2025), $921.0 million (Q4 2024), and $1.2 billion (Q4 2023), per Business Quant data.